patients

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

5 months ago

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

5 months ago

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

5 months ago

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging…

5 months ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

5 months ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

5 months ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

5 months ago

James Dyson Award announces its 2024 global winners: Hair-loss prevention device for chemotherapy patients and Sustainable ‘maple seed’ weather balloon

NEW DELHI, Nov. 14, 2024 /PRNewswire/ -- The James Dyson Award unveils its two global winners, each receiving £30,000 for solving…

5 months ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

5 months ago